ReviewAdvanced drug delivery reviews2021
Nanomedicine to fight infectious disease.
Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Green Nanotechnology: Naturally Sourced Nanoparticles as Antibiofilm and Antivirulence Agents Against Infectious Diseases.International journal of microbiology · 2025Review
- Decoding impact of human papillomavirus in gynecological oncology: a narrative review.Obstetrics & gynecology science · 2025Article
- Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.Pharmaceutics · 2024Review
- Article
- Nanoarchitectonics-Based Materials as a Promising Strategy in the Treatment of Endodontic Infections.Pharmaceutics · 2024Review
- Responsive Supramolecular Polymers for Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- Polymer-DNA assembled nanoflower for targeted delivery of dolastatin-derived microtubule inhibitors.RSC advances · 2024Article
- Determination of the Cytotoxicity and Antibiofilm Potential Effect of Equisetum arvense Silver Nanoparticles.Applied biochemistry and biotechnology · 2024Article
- Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.Pharmaceutics · 2023Review
- Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) Prepared by Microwave and Ultrasound-Assisted Synthesis: Promising Green Strategies for the Nanoworld.Pharmaceutics · 2023Review
- Nanomedicine and nanoparticle-based delivery systems in plastic and reconstructive surgery.Maxillofacial plastic and reconstructive surgery · 2023Review
- Emergence of microbial resistance against nanoparticles: Mechanisms and strategies.Frontiers in microbiology · 2023Review
- Current and prospective therapeutic strategies: tacklingFrontiers in cellular and infection microbiology · 2023Review
- Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections.Theranostics · 2023Review
- Functional Polymers as Innovative Tools in the Delivery of Antimicrobial Agents.Pharmaceutics · 2022Article
- Nanoparticle-Induced Augmentation of Neutrophils' Phagocytosis of Bacteria.Frontiers in pharmacology · 2022Article
- A Structural Approach to Anti-Virulence: A Discovery Pipeline.Microorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The ubiquity and potency of antibiotics may give the false impression that infection is a solved problem. Unfortunately, even bacterial infections, the target of antibiotics, remain a major cause of illness and death. Several major unmet needs persist: biofilms, such as those on implanted hardware, largely resist antibiotics; the inflammatory host response to infection often produces more damage than the infection itself; and systemic antibiotics often decimate the gut microbiome, which can predispose to additional infections and even predispose to non-infectious diseases. Additionally, there is an increasing threat from multi-drug resistant microorganisms, though market forces may continue to inhibit innovation in this realm. These numerous unmet infection-related needs provide attractive goals for innovation of targeted drug delivery technologies, especially those of nanomedicine. Here we review several of those innovations in pre-clinical development, the two such therapies which have made it to clinical use, and the opportunities for further technology development for treating infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.